A Single-arm, Open-label Clinical Study Evaluating the Efficacy and Safety of U01 (ssCART-19) in Patients With Relapsed or Refractory B-cell Lymphoma.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Incidence of Adverse events after U01 CAR-T cells infusion [Safety and Tolerability]
研究概览
简要总结
This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
详细描述
The primary objective of this study is to evaluate the efficacy and safety of CD19-targeted CAR-T cells engineered with an IL-6 silencing element in patients with relapsed or refractory B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent obtained from the participant (or legal guardian) with good compliance expected throughout the study.
- •All of the following conditions must be met:
- •Age 2-75 years at informed consent; both sexes eligible. For minors (≤18 years), consent must be provided by a parent/legal guardian; minors able to sign must co-sign with their guardian.
- •Histologically confirmed B-cell lymphoma per the 2024 v3 NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas.
- •Prior therapy requirements:
- •Failure to achieve PR after first-line therapy, OR relapse within 12 months after first-line therapy; or Relapsed/refractory after second-line therapy (one standard chemo-regimen + one salvage regimen).
- •Prior regimens must have included anti-CD20 monoclonal antibody (unless documented CD20-negative tumor) and an anthracycline-containing regimen. In addition, at least one of the following must apply:
- •i. Ineligible for autologous hematopoietic stem-cell transplantation (ASCT); ii. Refusal of ASCT; iii. Relapse after ASCT. d) Disease status at screening:
- •Relapse: progression after prior PR or CR.
- •Refractory: i. PD during/after last therapy, or best response ≤SD lasting <6 months; OR ii. Relapse or progression after ASCT (biopsy-proven), including relapse/PD ≤12 months post-ASCT or lack of response (SD/PD) to salvage therapy after ASCT.
- •Tumor tissue (archival or fresh) positive for CD19 by IHC; pathology report within 6 months preferred.
- •≥1 measurable lesion per Lugano 2014 response criteria.
- •ECOG performance status 0-
- •Adequate marrow reserve: ALC ≥0.3 × 10⁹/L; PLT ≥30 × 10⁹/L (transfusion permitted).
- •Adequate organ function:
- •AST ≤3×ULN (≤5×ULN if tumor-related); ALT ≤3×ULN (≤5×ULN if tumor-related);• Total bilirubin ≤2×ULN (≤3×ULN with direct bilirubin ≤1.5×ULN for Gilbert's syndrome);• Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault);• Pulmonary: ≤Grade 1 dyspnea and SpO₂ >91 % on room air;• LVEF ≥50 % by echocardiography;• INR ≤1.5×ULN and APTT ≤1.5×ULN.
- •Women of child-bearing potential: negative serum/urine pregnancy test within 7 days before CAR-T infusion. All participants with reproductive potential must use effective contraception from screening through ≥12 months after CAR-T infusion.
- •Adequate venous access for leukapheresis or repeated phlebotomy, with no contraindications to leukapheresis.
- •Estimated life expectancy >3 months.
排除标准
- •Concurrent malignancy other than the study indication, except for carcinoma in situ or any malignancy with a disease-free interval ≥3 years.
- •Presence of any of the following:• Positive HBe-Ab and/or HBc-Ab with HBV-DNA above the lower limit of quantification;• Positive HCV-Ab with HCV-RNA above the lower limit of quantification;• Positive Treponema pallidum antibody (TP-Ab);• Positive HIV antibody.
- •Active bacterial, fungal, viral, mycoplasmal, or other infection deemed uncontrollable by the investigator.
- •History or current clinically significant CNS disorder unrelated to lymphoma-e.g., seizure disorder, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any CNS autoimmune disease-that the investigator considers uncontrolled.
- •Within 12 months before informed consent: percutaneous coronary intervention (angioplasty or stent placement), NYHA Class III-IV congestive heart failure, myocardial infarction, unstable angina, or other clinically significant cardiac history judged by the investigator; or QTc >480 ms (Fridericia correction) or LVEF <50 % by echocardiography at screening.
- •Known primary immunodeficiency.
- •History of severe immediate hypersensitivity to any study drug.
- •Receipt of any live vaccine within 6 weeks before screening.
- •Pregnant or breastfeeding women.
- •Active autoimmune disease requiring systemic immunosuppressive therapy.
- •Participation in any other interventional clinical trial within 30 days before signing informed consent.
- •Any condition that, in the investigator's opinion, renders the subject unsuitable for study participation.
研究组 & 干预措施
U01(ssCART-19) CAR-T cells
CD19-targeted CAR-T cells engineered with an IL-6 silencing element
干预措施: ssCART-19 (Drug)
结局指标
主要结局
Incidence of Adverse events after U01 CAR-T cells infusion [Safety and Tolerability]
时间窗: 28 days post administration of ssCART-19
An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Overall survival (OS)
时间窗: 2 years post CAR T cell infusion
Overall Survival (OS) was defined as the time from the date of first infusion of U01 to the date of death due to any cause.
Progression-free survival (PFS)
时间窗: 2 years post CAR T cell infusion
Progression-free survival (PFS) was defined as the time from the date of infusion to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause.
Objective Response Rate (ORR), as assessed by Investigators
时间窗: 2 years post CAR T cell infusion
The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Remission (CR) or Partial Remission(PR)
Duration of response (DOR)
时间窗: 2 years post CAR T cell infusion
Duration of response (DOR) is defined as the time from the first documented objective response to the first documented disease progression or death.
次要结局
- Pharmacodynamics of ssCART-19(2 years post CAR T cell infusion)
- Pharmacokinetics of ssCART-19(2 years post CAR T cell infusion)